Clinical trials: Human Papillomavirus Infection, active
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs.
- Conditions
- Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases
- Trial name
- NCT07756840
- Testing
- PRGN-2012, Bevacizumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus Infection
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids.
- Trial name
- NCT07888686
- Testing
- 10vHPV, Gardasil9
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.
- Trial name
- NCT07601074
- Testing
- Lopinavir / ritonavir
- Where
- 8 sites in United States
- Volunteers
- 118 people
- Sponsor
- Daré Bioscience, Inc.
HPV (Human Papillomavirus)-Associated, Genital Warts
Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel
Phase II, a randomized, double-blind, placebo-controlled clinical trial to evaluate the effectiveness and recurrence of genital warts by combination of CO2 laser and Geniwa gel compared to laser CO2 combined with gel placebo.
- Trial name
- NCT07698886
- Testing
- Geniwa gel
- Where
- Vietnam
- Volunteers
- 70 people
- Sponsor
- KTH Biopharma
HSIL, High Grade Squamous Intraepithelial Lesion, CIN 2
Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2
This study evaluates the efficacy and safety of ALA-PDT versus LEEP in treating cervical HSIL/CIN2, aiming to demonstrate non-inferiority in clinical efficacy.
- Conditions
- HSIL, High Grade Squamous Intraepithelial Lesion, CIN 2, HPV (Human Papillomavirus)-Associated, Photodynamic Therapy (PDT)
- Trial name
- PDT for CIN2 (NCT07306260)
- Testing
- ALA-PDT, LEEP surgery
- Where
- 5 sites in China
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Human Papillomavirus Infection, Human Papillomavirus Infections
Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With Human Papillomavirus (HPV)
This randomized, open-label, multicenter clinical study is designed to evaluate Papilozumib® vaginal gel in women aged 30 to 50 years who test positive for human papillomavirus (HPV) and present with either normal cervical…
- Trial name
- NCT07762209
- Testing
- Papilozumib vaginal gel, Papilozumib oral supplement
- Where
- 6 sites in Spain
- Volunteers
- 81 people
- Sponsor
- Hifas da Terra S.L.
Human Papillomavirus Infection, Anal HPV Infection
Epidemiology of Anal Human Papillomavirus Carriage in Female Solid Organ Transplant Recipients With More Than 10 Years of Immunosuppression
Anal canal cancer is primarily associated with persistent infection by high-risk human papillomavirus (HR-HPV), particularly HPV-16.
- Conditions
- Human Papillomavirus Infection, Anal HPV Infection, Human Papillomavirus 16 Infection
- Trial name
- EPAHTOS (NCT07858201)
- Testing
- Anal Self-Sampling for High-Risk HPV Detection
- Volunteers
- 190 people
- Sponsor
- University Hospital, Montpellier
Cervical Carcinoma, Human Papillomavirus Infection
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention.
- Trial name
- SHIP-A-S01 (NCT06498661)
- Testing
- Biospecimen Collection, Cervical Biopsy, Colposcopy
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Warts, Plantar Warts
Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts
This clinical trial aims to compare the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of plantar warts.
- Conditions
- Warts, Plantar Warts, Human Papillomavirus Infection, Skin Diseases, Viral
- Trial name
- NCT07848100
- Testing
- Intralesional Acyclovir, Intralesional Zinc Sulphate
- Volunteers
- 76 people
- Sponsor
- Assiut University
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study
This study is extending follow up of women who participated in the Costa Rica Vaccine Trial (CVT) and received one dose or two doses of the human papillomavirus (HPV) vaccine, along with a group of women who received three doses.
- Trial name
- NCT03309033
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- Costa Rica
- Volunteers
- 946 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
ESCUDDO Long Term Follow Up
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
- Trial name
- ESCUDDO LTFU (NCT07706673)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- Costa Rica
- Volunteers
- 13,700 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HIV Infection, Human Papillomavirus-Related Cervical Carcinoma
Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
Background In sub-Saharan Africa (SSA), human papillomavirus (HPV) and HIV create a dual burden of disease that causes significant morbidity and mortality in the form of cervical cancer (CC).
- Conditions
- HIV Infection, Human Papillomavirus-Related Cervical Carcinoma, Screening Strategy
- Trial name
- NCT06708351
- Testing
- Best Practice, Health Promotion and Education, HPV Self-Collection
- Where
- Kenya
- Volunteers
- 2,280 people, healthy volunteers welcome
- Sponsor
- Emory University
Human Papillomavirus Infection
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
This long-term extension study evaluates the persistence of neutralizing antibody responses to a bivalent human papillomavirus vaccine in females who previously participated in study 311-HPV-1004 (NCT02740777).
- Trial name
- NCT07820241
- Testing
- Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)
- Where
- 2 sites in China
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children
This study will evaluate the safety and immune response of a single dose of a quadrivalent human papillomavirus (HPV) vaccine when given together with a tetanus-diphtheria (Td) vaccine in healthy children and adolescents aged 9…
- Trial name
- NCT07824310
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster
- Where
- Indonesia
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Immunization, HPV Infection
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response.
- Conditions
- Immunization, HPV Infection, Human Papillomavirus
- Trial name
- NCT05672927
- Testing
- 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period…
- Trial name
- NCT03036930
- Testing
- Biospecimen Collection, HPV Self-Collection, Questionnaire Administration
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus (HPV) Vaccines
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low.
- Trial name
- NCT03429413
- Testing
- Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
- Where
- United States
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of Florida
Cervical Intraepithelial Neoplasia Grade 1, Human Papillomavirus 16 Infection
Phase I/II Trial of Electroporation-Delivered pBI-4 Vaccine (TriGrid™ PVX4) for Treatment of Women With HPV16-Positive CIN1 or Persistent Infection
The purpose of this study is to evaluate the safety, efficacy, and tolerability of pBI-4, an investigational therapeutic DNA vaccine, in treating adult women with Human Papillomavirus type 16 (HPV16)-positive Grade 1 cervical…
- Trial name
- NCT07809997
- Testing
- pBI-4 Vaccine
- Where
- 2 sites in Taiwan
- Volunteers
- 94 people
- Sponsor
- Chang Gung Memorial Hospital
Anal Carcinoma, Cervical Carcinoma
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls.
- Conditions
- Anal Carcinoma, Cervical Carcinoma, Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
- Trial name
- NCT00867464
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Long-term Follow-up
- Where
- Costa Rica
- Volunteers
- 8,670 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)